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Concern exists that liver transplant center substance
abuse policies may have an inappropriate and dispro-
portionate impact on marijuana users. Our hypoth-
esis is that patients with chronic liver disease who
were marijuana users will have inferior survival. This
is a retrospective (1999–2007) cohort study. The pri-
mary outcome measure is time-dependent, adjusted
patient survival from the time of liver transplant
evaluation. The primary exposure variable is a positive
cannabinoid toxicology screen during the liver trans-
plant evaluation period. Overall, 155 patients quali-
fied as marijuana users while 1334 patients were mar-
ijuana non-users. Marijuana users were significantly
(p < 0.05) younger (48.3 vs. 52.1), more likely to be
male (78.1% vs. 63.0%), have hepatitis C (63.9% vs.
40.6%) and were less likely to receive a transplant
(21.8% vs. 14.8%). Marijuana users were more likely
to use tobacco, narcotics, benzodiazepines, am-
phetamines, cocaine or barbiturates (p < 0.05). Un-
adjusted survival rates were similar between cohorts.
Upon multivariate analysis, MELD score, hepatitis C
and transplantation were significantly associated with
survival, while marijuana use was not (HR 1.09, 95%
CI 0.78–1.54). We conclude that patients who did and
did not use marijuana had similar survival rates. Cur-
rent substance abuse policies do not seen to system-
atically expose marijuana users to additional risk of
mortality.
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Introduction
Marijuana is the most prevalently used illegal substance in
the United States (1). Nearly 40% of American teenagers
have tried marijuana in their lifetimes and almost 20% in-
dicate they are current users (2). Among adults, estimates
stand at just over 38% for one-time users with 3.5% iden-
tifying themselves as current users (3). In addition, the le-
gality of marijuana use, both recreational and medicinal, re-
mains controversial. There are significant potential benefits
of cannabinoid use, including therapeutic effects on cancer,
appetite, pain control, seizure disorder and glaucoma (4–7).
In contrast, marijuana has significant detrimental effects on
cognitive-motor skills, as well as memory and attention per-
formance, among others (8,9). Perhaps because of these
adverse affects on health and performance, marijuana use
carries a stigma that can affect the lives of users, including
candidates for liver transplantation.
Even though marijuana use (both legal and illegal) remains
a controversial issue, in general, the issue is much less
controversial within the liver transplant professional com-
munity. For example, liver transplant centers in UNOS Re-
gion 10 have maintained a policy of marijuana abstinence
for any ambulatory patient to be considered a liver trans-
plant candidate (10). In addition, patients are required to
abstain from alcohol and all other illicit drugs. Patients fre-
quently test positive for marijuana, and other substances,
at the time of their initial liver transplant evaluation. These
patients and others who are thought to have significant
substance abuse issues are offered resources to facili-
tate abstinence. The transplant evaluation committee de-
termines requirements for listing which usually entail both
a period of abstinence (generally 6 months) and comple-
tion of an approved substance abuse counseling program.
In addition, before any patient is listed for transplant, all
ambulatory candidates are required to sign the Region 10
substance abuse policy. To prove their compliance with
this policy, patients are subjected to blood and urine tox-
icology screening until transplantation. If a patient tests
positive for a prohibited substance after signing this sub-
stance abuse policy, he or she will no longer be consid-
ered a candidate for liver transplantation at any center in
Region 10.
Substance abuse policies are necessary to help ensure that
potential liver transplant recipients will be reliable stew-
ards of the new organ. Despite this, concern exists that
substance abuse policies may have an inappropriate and
disproportionate impact on marijuana users. Firstly, many
in the general public would argue that marijuana users
should not have limited access to transplantation, partic-
ularly within the context of medical marijuana (6, 11). As
an example, in May 2008, significant press coverage was
given to the case of Timothy Garon, who reportedly died af-
ter having been refused a liver transplant, in part, because
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of his use of medical marijuana (12). Secondly, current tox-
icology screening methods produce a positive toxicology
screen for cannabinoids up to two months after the pa-
tient’s last use (13). In contrast, other toxicology screening
tests such as those for cocaine and alcohol become nega-
tive shortly after use. As a result, it may be more difficult for
chronic marijuana users to demonstrate abstinence prior to
life-ending decompensation of their liver disease.
Within this context, our hypothesis is that patients with
chronic liver disease who are marijuana users will have
inferior survival. We define marijuana user as anyone who
had a positive toxicology screen for cannabinoids from the
time of liver transplant evaluation. In order to address this
hypothesis, we compared the survival of all patients who
were marijuana users to marijuana non-users.
Methods
Patients
Data collection and analysis was approved by the University of Michigan In-
stitutional Review Board for this retrospective cohort study. All data was col-
lected from the University of Michigan electronic medical record and from a
prospectively collected transplant database. All adult patients with chronic
liver disease evaluated for liver transplant at the University of Michigan
between January 1, 1999 and June 1, 2007 were included in the study
group. Clinical data was collected on all patients, including: demographic
data, Model for End-Stage Liver Disease (MELD) score components (INR,
creatinine and bilirubin at the time of evaluation, listing and transplanta-
tion), and the etiology of liver disease. In addition, dates were collected for:
evaluation, listing, transplantation, death and last follow-up.
Patients with insufficient toxicology data were excluded from analysis.
‘users’ were documented by the presence of a positive toxicology screen
between the date of evaluation for liver transplant and either date of trans-
plantation or most recent follow-up. Moreover, the patient was considered
a marijuana user only if they had documented cannabinoids on toxicology
screen. If the patient reported marijuana use by history, but there toxicology
screen was negative, they were not considered a user. The substances of
interest included: cannabinoids, narcotics, benzodiazepines, ethanol, am-
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Figure 1: Flow chart detail-
ing the listing and transplant
status of 1489 patients with
chronic liver disease evalu-
ated for a liver transplant
at the University of Michi-
gan, stratified by whether or
not the were marijuana users.
Marijuana user is defined as any
patient with a positive urine tox-
icology screen for cannabinoids
between the date of evaluation
for liver transplant and either
date of transplantation or most
recent follow-up.
of transplant evaluation and the presence of any psychiatric hospitalization
over the life span of these patients were also noted.
Statistical analysis
The primary exposure variable for this analysis was marijuana user. Differ-
ences in demographics, substance use, hepatitis C and MELD scores were
compared between the two study groups using standard univariate analysis.
Categorical variables were analyzed using chi-square analysis. Continuous
variables were assessed with a two-tailed Students t-test.
Unadjusted rates the patient survival between marijuana users and mari-
juana non-users were calculated by the method of Kaplan and Meier. The
independent effects of marijuana use the patient survival were assessed
using multivariable Cox proportional hazards model. A single model was
created to analyze time to event outcomes (mortality) from the time the
liver transplant evaluation to death or end of follow-up. Potential covariates
for entry into the multivariate model were determined to be clinically rele-
vant and/or to have a significant level on univariate assessment of p < 0.10.
All tests used were 2-sided and a p-value of less than 0.05 was considered
to be statistically significant. SPSS V15.0 (Chicago, IL) was used for data
analysis.
Results
A total of 2292 adult patients with chronic liver disease
were evaluated for liver transplantation at the Univer-
sity of Michigan between Jaunary 1, 1999 and June 1,
2007. Some patients did not have complete data regard-
ing toxicology, smoking or psychiatric history (n = 803).
Upon exclusion of these patients, 1489 patients remained.
(Figure 1) Of these, 155 were marijuana users and 1334
were marijuana non-users. With respect to listing for trans-
plant, 43 (27%) of marijuana users were listed compared
to the 593 (44%) of non-users. The 43 marijuana users
who were listed for transplant had fulfilled the substance
abuse specific requirements of the liver transplant eval-
uation committee. Of those listed, a significantly larger
proportion of marijuana non-users were transplanted com-
pared to marijuana users (21.8% vs. 14.8%, p = 0.048).
In addition, of the 155 marijuana users, 145 tested posi-
tive prior to signing the substance abuse policy, 43 of these
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Figure 2: Flow chart detailing the
listing and liver transplant status of
155 patients who were marijuana
users. Marijuana user is defined as any
patient with a positive urine toxicology
screen for cannabinoids between the
date of evaluation for liver transplant
and either date of transplantation or
most recent follow-up.
patients were listed and 23 received a transplant (Figure 2).
There were 10 patients who tested positive after signing
the substance abuse policy and they were removed from
the transplant list and did not receive a transplant.
Comparing patient characteristics between marijuana
users and non-users (Table 1), revealed that marijuana
users were younger (48.3 ± 9.2 vs. 52.1 ± 9.4, p = 0.001)
and more likely to be male (78.1% vs. 63.0%, p = 0.001).
A significantly higher proportion of the marijuana users had
a diagnosis of hepatitis C (63.9% vs. 40.6%, p = 0.001).
Interestingly, the marijuana users had lower MELD scores
at evaluation than non-users (10.7 ± 5.1 vs. 12.4 ± 6.9, p =
0.004). Racial and psychiatric backgrounds were relatively
similar between the two study cohorts.
Between our two groups, the marijuana users and non-
users, we compared the presence of other substances
noted on toxicology screen. The marijuana users were
more likely to have narcotics, benzodiazepines and other
substances including barbiturates, amphetamines and co-
caine in their system. Marijuana users were not sig-
nificantly more likely to have a positive serum alcohol
level (3.9% vs. 2.2%, p = 0.164). Marijuana users were
significantly more likely to be active smokers on the
Table 1: Clinical characteristics of patients evaluated for a liver transplant stratified by whether they have a positive toxicology screen for
marijuana
Positive marijuana Negative marijuana
(n = 155) (n = 1334) p-Value
Age at liver evaluation 48.3 ± 9.2 52. 1 ± 9.4 0.001
Sex (% male) 78.1% 63.0% 0.001
Race (% non-black) 81.3% 82.5% 0.696
Positive hepatitis C status 63.9% 40.6% 0.001
MELD at evaluation 10.7 ± 5.1 12.4 ± 6.9 0.004
Positive transplant status 14.8% 21.8% 0.048
Positive psychiatric hospitalization 3.2% 2.6% 0.600
Positive smoker 57.1% 35.6% 0.001
Positive ethanol 3.9% 2.2% 0.164
Positive narcotics 31.0% 19.9% 0.002
Positive benzodiazepines 21.9% 10.0% 0.001
Positive other substances 7.7% 2.6% 0.002
day of the liver transplant evaluation (57.1% vs. 35.6%,
p = 0.001).
The unadjusted survival rates from the time of liver trans-
plant evaluation were similar between the two study co-
horts (marijuana users and marijuana non-users) (Figure 3).
Importantly, patients were censored at death and end of
follow-up, but not at transplantation.
We then assessed the independent effects on marijuana
detection among patients with chronic liver disease evalu-
ated for a liver transplant. As is demonstrated in Figure 3,
marijuana uses did not have a significantly higher hazard
of mortality (HR 1.09, 95% CI 0.78–1.54) (Figure 4). Co-
variates independently associated with hazard of mortality
were age at evaluation (HR 1.03, 95%CI 1.02–1.04), meld
at evaluation (1.01, 95% CI 1.09–1.12), positive hepatitis C
(HR 1.75, 95% CI 1.41–2.17) and transplantation (HR 0.75,
95% CI 0.65–0.86).
Discussion
In the study, we assessed the independent effects of mar-
ijuana detection on the survival of patients with chronic
282 American Journal of Transplantation 2009; 9: 280–285
Marijuana Use among Liver Transplant Candidates
Figure 3: Kaplan–Meier survival curve of 1489 patients with
chronic liver disease, evaluated for a liver transplant at the
University of Michigan. When marijuana users were compared
to marijuana non-users, no significant differences in unadjusted
patient survival were noted. Patients were censored at death or
end of follow-up, but not at transplant.
liver disease who were evaluated for liver transplantation.
We found that patients who tested positive for marijuana
had similar survival rates compared to patients that did not
test positive. Our group became interested in this topic
because of concern that are current substance abuse poli-
cies may have a significant and disproportionate impact on
marijuana users. Interestingly, our results did not support
our hypothesis that marijuana users would have inferior
survival.
No previous studies have specifically looked at substance
abuse within the context of overall survival (pre- and post-
transplant) among patients with chronic liver disease. In
Figure 4: Results of a multivariable
Cox proportional hazards model cre-
ated to analyze time to event out-
comes (mortality) from the time the
liver transplant evaluation to death or
end of follow-up. Marijuana use was
not significantly associated with differ-
ences in the hazard of mortality.
fact, little data exists about the implications of substance
abuse on transplant outcomes, in general. There are data
documenting the deleterious effects of continued use of
alcohol on the long-term survival of liver-transplant recipi-
ents (14). In contrast, evidence regarding other substances
is less compelling. One small study demonstrated similar
outcomes for patients who did and did not relapse to poly-
substance abuse following transplantation (15). One sub-
stance that more clearly seems to be associated with infe-
rior outcomes among transplantation patients is cigarette
smoking (16–20). Despite these data, cigarette smoking
is not contraindicated by our and presumably other, liver
transplant substance abuse policies.
The clinical implications of marijuana use are diverse, and
potentially both harmful and beneficial. The health risks
of marijuana use are well documented: including dose-
dependent respiratory symptoms such as shortness of
breath, coughing and increased sputum production (21–
24). Long-term marijuana abuse is associated with cog-
nitive deficits, as well as with cerebrovascular disorders
such as stroke (25). Isolated incidents of severe Aspergillo-
sis fumigatus infection from contaminated marijuana have
occurred in transplant recipients (26–28). Interestingly, en-
docannabinoids, endogenous cannabinoids that bind to
the same CB1 and CB2 receptors as tetrahydrocannabi-
nol (THC), the active component in marijuana, are highly
upregulated in chronic liver disease and may contribute
to the pathogenesis of various liver diseases (29,30). This
finding suggests that cannabinoids could exacerbate liver
disease (29). In contrast to the potential deleterious effects
of marijuana, it may provide some therapeutic effects for
patients with liver disease. Marijuana use has been shown
to positively affect various neurological and psychological
phenomena such as mood, appetite, analgesia and nau-
sea control (29,31–33). In addition, cannabinoids have been
shown to possess immunomodulatory and antiinflamma-
tory properties in peripheral tissues via CB2 receptor acti-
vation, potentially reducing the risk of rejection (31,34).
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Though this study is the first to provide a comprehen-
sive assessment of marijuana use among patients with
chronic liver disease, it has several important limitations.
First, since the data his retrospective in nature, attribut-
ing a cause and effect relationship between marijuana use
and mortality is not possible. Secondly, this single cen-
ter study reports upon a relatively small sample size of
patients. As a result of the small sample size, we were un-
able to address the important issue of the implications of
posttransplant marijuana use. Thirdly, considering the com-
plexity of the patients studied and how little work has been
done describing the relationship between substance abuse
and outcomes in liver disease, there are likely confound-
ing factors not considered by our multivariable model. Im-
portantly, toxicology screening data was absent for a sig-
nificant number of patients. The vast majority of these
patients did not undergo a full pretransplantation clinical
evaluation, presumably because they were not thought to
be transplant candidates. We do not know if these pa-
tients were not candidates because there were two well
or to sick. In addition, our definition of marijuana use as a
positive toxicology screen on or after the date of evalua-
tion does not capture certain details of patients’ marijuana
habits, particularly frequency and duration. Subsequently,
marijuana use was managed as a simple covariate in our
survival model, rather than a time-dependent covariate.
Other covariates (Age, MELD score, hepatitis C diagno-
sis, etc.) have previously been shown to affect survival
among cirrhotics (35,36). These covariates, in part, con-
trolled for the severity of illness, but did not account for
the dynamics of illness severity. Despite these important
limitations, our work does represent a timely and compre-
hensive assessment of a poorly studied the area in liver
transplantation.
Overall, the survival of marijuana users, as defined by
this manuscript, with chronic liver disease who present
for transplant evaluation is not significantly different from
marijuana non-users. From these findings, we are able to
conclude that marijuana users are not systematically ex-
posed to excess risk of mortality because of the current
substance abuse policies used by our center or other cen-
ters in UNOS region 10. This is likely in part due to the hard
work of our dedicated transplant team members, who ed-
ucate and rehabilitate the substance abusers who are eval-
uated by our liver transplant program. Continued study of
liver transplant substance abuse policies is necessary to
assure that these policies consider the beliefs of patients,
transplant professionals, donor families and the public, in
general.
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